{
  "pmcid": "10761379",
  "sha256": "361c1f203e2a88f02467dab2ec1aa56468ba62a85693de33cbfc3fc58b177c4d",
  "timestamp_utc": "2025-11-09T21:56:39.925735+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.171646098348209,
    "reading_ease": 32.70118283652934,
    "word_count": 229
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of TPF Chemotherapy Followed by Surgery in Borderline Resectable Esophageal Squamous Cell Carcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This single-center phase 2 trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients aged 18–70 with histologically confirmed BR-ESCC at Sun Yat-sen University Cancer Center"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention involved TPF chemotherapy followed by surgery if resectable, or concurrent chemoradiation if unresectable."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the impact of docetaxel, cisplatin, and fluorouracil (TPF) chemotherapy followed by surgery on survival in patients with borderline resectable esophageal squamous cell carcinoma (BR-ESCC)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the R0 resection rate, measured post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between July 2004 and February 2019, 47 patients were enrolled."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Surgery was performed on 27 patients (57.4%), achieving R0 resection in 25 (53.2%)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The median overall survival (OS) was 41.9 months (95% CI, 18.6–65.3), and median progression-free survival (PFS) was 38.7 months (95% CI, 23.5–53.9)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No serious perioperative complications or deaths were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The study was registered at ClinicalTrials.gov (NCT02976909)."
      },
      "Funding": {
        "score": 1,
        "evidence": "The trial was funded by Sun Yat-sen University Cancer Center."
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}